Newswire and Healthcare Information

Analgesic Signal Observed Iselin NJ, April 24, 2006 – Pharmos Corporation (Nasdaq: PARS) today announced results from its Phase 2a clinical trial of the effects of intravenous (i.v.) cannabinor against post-operative pain in over 100 male patients undergoing third molar dental extraction. The single-center, randomized, double-blinded, placebo-controlled, single administration of different cannabinor doses study was conducted at the UCL (University College London) Analgesia Centre in London, […]

Israeli Government Office of the Chief Scientist Awards US $1.5 Million to Fund Development of Cannabinoid Compounds and NanoEmulsion Drug Delivery System Iselin NJ, March 29, 2007 – Pharmos Corporation (Nasdaq: PARS) today announced it has been awarded a grant of up to US$ 1.5 million by the Office of the Chief Scientist (OCS) of Israel’s Ministry of Industry and Trade. The funds have been granted […]

Iselin NJ, March 15, 2007 – PPharmos Corporation (Nasdaq: PARS) today reported results for the 12-month period and fourth quarter ended December 31, 2006. The major highlight of 2006 was the acquisition by Pharmos of Vela Pharmaceuticals Inc. (Vela), which closed in the fourth quarter. The transaction resulted in an expansion of Pharmos’ pipeline with later-stage clinical drug candidates including dextofisopam, a promising and innovative new […]

Iselin NJ, February 26, 2007 – Pharmos Corp. (NASDAQ: PARS) announced today that Elkan Gamzu, Ph.D., has been appointed by the Board of Directors to become Chief Executive Officer, effective March 31, 2007. He will succeed Haim Aviv, Ph.D., who will be retiring on that date. Dr. Aviv will continue as Chairman of the Board. Dr. Gamzu, a Director of the Company since February 2000, is […]

Iselin NJ, January 19, 2007 – Pharmos Corp. (NASDAQ: PARS) today announced preliminary results from its Phase 2a study evaluating intravenous (i.v.) cannabinor, a CB2-selective synthetic cannabinoid compound, in a capsaicin-induced pain model. The drug candidate did not meet the primary endpoint defined by analgesic effects compared to placebo, but confirmed safety and tolerability observed in previous studies. All subjects completed the treatment with no serious […]

Positive Safety Data Support Clinical Trials of Oral Cannabinor Iselin NJ, December 14, 2006 Pharmos Corp. (NASDAQ: PARS) today announced the completion of preclinical toxicology and safety pharmacology studies of an oral formulation of cannabinor, a synthetic CB2-selective agonist, to support dosing in humans. The toxicology studies included maximum tolerated dose (MTD) studies, a 28-day repeat-dose study, and a cardiovascular safety study in animals. Results of […]

Iselin NJ, December 11, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that President and COO Alan L. Rubino will participate in a gastroenterology-focused panel discussion on Wednesday, December 13, 2006 at 9:00 AM Eastern Time as part of the 2006 RBC Capital Markets Healthcare Conference taking place at the Westin New York at Times Square in New York City. An audio-only webcast and replay of […]

Iselin NJ, December 5, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that due to a late change in the conference agenda for the BMO Capital Markets Focus on Healthcare Conference, President and COO Alan L. Rubino will present at 10:30 am Eastern Time on Thursday, December 7, 2006. The conference is taking place December 6-7, 2006 at the Millennium Broadway Hotel in New York, New […]

Iselin NJ, November 30, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that President and COO Alan L. Rubino will present at the BMO Capital Markets Focus on Healthcare Conference on Thursday, December 7, 2006 at 11:00 AM Eastern Time. The conference is taking place December 6-7, 2006 at the Millennium Broadway Hotel in New York, New York. A webcast of Pharmos’ presentation will be available […]

Data Indicate Positive Results Achieved on Safety, Tolerability and Pharmacokinetics Iselin NJ, June 29, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today it has completed its initial analysis of data from a recently completed Phase 1 study of its proprietary NanoEmulsion topical drug delivery technology formulated with diclofenac. Diclofenac is an approved and widely-used non-steroidal anti-inflammatory drug (NSAID). The analysis of the data indicates the formulation […]